Irinotecan News and Research

RSS
Irinotecan hydrochloride is approved by the Food and Drug Administration (FDA) to be used with other drugs to treat colorectal cancer that has metastasized (spread to other parts of the body). It is also approved to treat metastatic colorectal cancer that has recurred (come back) or gotten worse after earlier chemotherapy. In addition to the uses that have been approved by the FDA, irinotecan hydrochloride is sometimes used to treat other types of cancer. Irinotecan hydrochloride is also being studied in the treatment of other types of cancer.
Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Multi-strain probiotic helps reduce chemotherapy-induced diarrhea in cancer patients

Comprehensive analysis reveals weaknesses to target in common pediatric solid tumor

Comprehensive analysis reveals weaknesses to target in common pediatric solid tumor

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Researchers explore targeted second-line treatment for colorectal cancer

Researchers explore targeted second-line treatment for colorectal cancer

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

Study confirms safety and efficacy of new second line treatment for metastatic colorectal cancer

Gut bacteria composition could predict toxicity of chemotherapy drugs in cancer patients

Gut bacteria composition could predict toxicity of chemotherapy drugs in cancer patients

FDA grants approval for new biosimilar to treat multiple types of cancer

FDA grants approval for new biosimilar to treat multiple types of cancer

St. Jude creates world’s largest collection of pediatric solid tumor samples

St. Jude creates world’s largest collection of pediatric solid tumor samples

HHMI scientists expand access to new resource for studying pediatric cancers

HHMI scientists expand access to new resource for studying pediatric cancers

IQWiG finds colorectal cancer drug combination has added benefit only for some patients

IQWiG finds colorectal cancer drug combination has added benefit only for some patients

DNA-binding protein CHD1 could be potential biomarker for targeted prostate cancer treatment

DNA-binding protein CHD1 could be potential biomarker for targeted prostate cancer treatment

Study uncovers new drug-gene mutation combinations that can kill cancer cells

Study uncovers new drug-gene mutation combinations that can kill cancer cells

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Novel anti-interleukin 1-alpha antibody shows promise in treating advanced colorectal cancer patients

Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

Study shows safety of experimental drug guadecitabine in colorectal cancer patients